Choudhury Chinmayee, Bhardwaj Anshu
Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Bioinformatics Centre, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh, India.
Front Chem. 2020 Dec 2;8:596412. doi: 10.3389/fchem.2020.596412. eCollection 2020.
Antimicrobial resistance (AMR) is one of the most serious global public health threats as it compromises the successful treatment of deadly infectious diseases like tuberculosis. New therapeutics are constantly needed but it takes a long time and is expensive to explore new biochemical space. One way to address this issue is to repurpose the validated targets and identify novel chemotypes that can simultaneously bind to multiple binding pockets of these targets as a new lead generation strategy. This study reports such a strategy, dynamic hybrid pharmacophore model (DHPM), which represents the combined interaction features of different binding pockets contrary to the conventional approaches, where pharmacophore models are generated from single binding sites. We have considered Mtb-DapB, a validated mycobacterial drug target, as our model system to explore the effectiveness of DHPMs to screen novel unexplored compounds. Mtb-DapB has a cofactor binding site (CBS) and an adjacent substrate binding site (SBS). Four different model systems of Mtb-DapB were designed where, either NADPH/NADH occupies CBS in presence/absence of an inhibitor 2, 6-PDC in the adjacent SBS. Two more model systems were designed, where 2, 6-PDC was linked to NADPH and NADH to form hybrid molecules. The six model systems were subjected to 200 ns molecular dynamics simulations and trajectories were analyzed to identify stable ligand-receptor interaction features. Based on these interactions, conventional pharmacophore models (CPM) were generated from the individual binding sites while DHPMs were created from hybrid-molecules occupying both binding sites. A huge library of 1,563,764 publicly available molecules were screened by CPMs and DHPMs. The screened hits obtained from both types of models were compared based on their Hashed binary molecular fingerprints and 4-point pharmacophore fingerprints using Tanimoto, Cosine, Dice and Tversky similarity matrices. Molecules screened by DHPM exhibited significant structural diversity, better binding strength and drug like properties as compared to the compounds screened by CPMs indicating the efficiency of DHPM to explore new chemical space for anti-TB drug discovery. The idea of DHPM can be applied for a wide range of mycobacterial or other pathogen targets to venture into unexplored chemical space.
抗菌药物耐药性(AMR)是全球最严重的公共卫生威胁之一,因为它会影响结核病等致命传染病的成功治疗。人们一直需要新的治疗方法,但探索新的生化空间需要很长时间且成本高昂。解决这一问题的一种方法是重新利用经过验证的靶点,并识别能够同时结合这些靶点多个结合口袋的新型化学类型,以此作为一种新的先导化合物发现策略。本研究报告了这样一种策略,即动态混合药效团模型(DHPM),它代表了不同结合口袋的组合相互作用特征,这与传统方法相反,传统方法中的药效团模型是从单个结合位点生成的。我们将结核分枝杆菌天冬氨酸β-半醛脱氢酶(Mtb-DapB)作为一个经过验证的分枝杆菌药物靶点,作为我们的模型系统来探索DHPM筛选新型未探索化合物的有效性。Mtb-DapB有一个辅因子结合位点(CBS)和一个相邻的底物结合位点(SBS)。设计了四种不同的Mtb-DapB模型系统,在相邻的SBS中,无论有无抑制剂2,6-二吡啶羧酸(2,6-PDC),烟酰胺腺嘌呤二核苷酸磷酸(NADPH)/烟酰胺腺嘌呤二核苷酸(NADH)都占据CBS。还设计了另外两种模型系统,其中2,6-PDC与NADPH和NADH相连形成杂合分子。对这六种模型系统进行了200纳秒的分子动力学模拟,并分析轨迹以识别稳定的配体-受体相互作用特征。基于这些相互作用,从各个结合位点生成传统药效团模型(CPM),而从占据两个结合位点的杂合分子创建DHPM。用CPM和DHPM筛选了一个包含1563764个公开可用分子的大型文库。根据哈希二元分子指纹和四点药效团指纹,使用塔尼莫托(Tanimoto)、余弦、迪西(Dice)和特弗斯基(Tversky)相似性矩阵,比较了从两种模型获得的筛选命中物。与CPM筛选的化合物相比,DHPM筛选的分子表现出显著的结构多样性、更好的结合强度和类药物性质,这表明DHPM在探索抗结核药物发现的新化学空间方面的效率。DHPM的理念可应用于广泛的分枝杆菌或其他病原体靶点,以探索未开发的化学空间。